193 related articles for article (PubMed ID: 30980038)
21. Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With "Single-cell" Growth Reveals 2 Distinct Types, One With "Plasmacytoid" Features.
Nguyen JK; Chen YY; Magi-Galluzzi C; McKenney JK
Am J Surg Pathol; 2020 Dec; 44(12):1635-1642. PubMed ID: 32991340
[TBL] [Abstract][Full Text] [Related]
22. Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer.
Goltz D; Montani M; Braun M; Perner S; Wernert N; Jung K; Dietel M; Stephan C; Kristiansen G
Pathology; 2015 Dec; 47(7):629-36. PubMed ID: 26517642
[TBL] [Abstract][Full Text] [Related]
23. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen TA; Määttänen L; Stenman UH; Tammela T; Hakama M; Visakorpi T
J Urol; 2001 May; 165(5):1569-74. PubMed ID: 11342919
[TBL] [Abstract][Full Text] [Related]
24. Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.
Chen Y; Lin Y; Nie P; Jiang W; Liu Y; Yuan R; Li M; Zhao S; Lin H; Li P; Zhang J; Hu Z; Xu J; Zhu X
Med Sci Monit; 2017 Apr; 23():1768-1774. PubMed ID: 28400549
[TBL] [Abstract][Full Text] [Related]
25. BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.
Schwartz AM; Man YG; Rezaei MK; Simmens SJ; Berg PE
Mod Pathol; 2009 Jan; 22(1):1-6. PubMed ID: 18931648
[TBL] [Abstract][Full Text] [Related]
26. Prognostic markers in clinically localised prostate cancer.
Bai XZ; Masters JR; O'Donoghue N; Kirby R; Pan LX; Young M; Stafford M; Parkinson MC
Int J Oncol; 1999 Apr; 14(4):785-91. PubMed ID: 10087330
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma.
Sakai H; Yogi Y; Minami Y; Yushita Y; Kanetake H; Saito Y
J Urol; 1993 May; 149(5):1020-3. PubMed ID: 7683340
[TBL] [Abstract][Full Text] [Related]
28. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
29. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
30. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.
Gunia S; Albrecht K; Koch S; Herrmann T; Ecke T; Loy V; Linke J; Siegsmund M; May M
World J Urol; 2008 Jun; 26(3):243-50. PubMed ID: 18392627
[TBL] [Abstract][Full Text] [Related]
31. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
32. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.
Fisher G; Yang ZH; Kudahetti S; Møller H; Scardino P; Cuzick J; Berney DM;
Br J Cancer; 2013 Feb; 108(2):271-7. PubMed ID: 23329234
[TBL] [Abstract][Full Text] [Related]
34. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
[TBL] [Abstract][Full Text] [Related]
35. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
36. [The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progresion of the prostate cancer after radical prostatectomy].
Ojea Calvo A; Mosteiro Cerviño MJ; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A
Actas Urol Esp; 2004 Oct; 28(9):650-60. PubMed ID: 16050199
[TBL] [Abstract][Full Text] [Related]
37. High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade.
Abouelfadel Z; Miller GJ; Glode LM; Akduman B; Donohue RE; Nedrow A; Crawford ED
Clin Prostate Cancer; 2002 Sep; 1(2):115-7. PubMed ID: 15046702
[TBL] [Abstract][Full Text] [Related]
38. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
[TBL] [Abstract][Full Text] [Related]
39. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Hammarsten P; Karalija A; Josefsson A; Rudolfsson SH; Wikström P; Egevad L; Granfors T; Stattin P; Bergh A
Clin Cancer Res; 2010 Feb; 16(4):1245-55. PubMed ID: 20145160
[TBL] [Abstract][Full Text] [Related]
40. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
